Effects of Angiotensin-Converting Enzyme Inhibitors in Systolic Heart Failure Patients With Chronic Kidney Disease: A Propensity Score Analysis

Journal of Cardiac Failure

Volumn 12, Issue 7, 2006, Pages 499-506

  Ahmed, Ali ^a   Love, Thomas E ^b   Sui, Xuemei ^c   Rich, Michael W ^d  

^a Nutrition Sciences and Medicine   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c the Cooper Institute ^*  (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Chronic kidney disease; Heart failure; Hospitalization; Mortality

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CALCULATION; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SYSTOLE;

EID: 33748356053     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.05.008     Document Type: Article

References (38)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
2. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
3. Ruggenenti P., Perna A., and Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12 (2001) 2832-2837
4. Locatelli F., Carbarns I.R., Maschio G., et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int Suppl 63 (1997) S63-S66
5. Strippoli G.F., Craig M., Deeks J.J., Schena F.P., and Craig J.C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329 (2004) 828
6. Bart B.A., Gattis W.A., Diem S.J., and O'Connor C.M. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 79 (1997) 1118-1120
7. Frances C.D., Noguchi H., Massie B.M., Browner W.S., and McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 160 (2000) 2645-2650
8. Ahmed A., Kiefe C.I., Allman R.M., Sims R.V., and DeLong J.F. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 50 (2002) 1659-1666
9. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006) 671-678
10. Ahmed A., Centor R., Weaver M.T., and DeLong J.F. A propensity score analysis of the impact of ACE inhibitors on 4-year survival of older adults with heart failure and perceived contraindications. Am Heart J 149 (2005) 737-743
11. Shlipak M.G. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 138 (2003) 917-924
12. The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials 17 (1996) 77-97
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
14. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
15. Rule A.D., Larson T.S., Bergstralh E.J., Slezak J.M., Jacobsen S.J., and Cosio F.G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141 (2004) 929-937
16. Chae C.U., Albert C.M., Glynn R.J., Guralnik J.M., and Curhan G.C. Mild renal insufficiency and risk of congestive heart failure in men and women > or = 70 years of age. Am J Cardiol 92 (2003) 682-686
17. Shlipak M.G., Stehman-Breen C., Fried L.F., et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis 43 (2004) 861-867
18. Shlipak M.G., Fried L.F., Stehman-Breen C., Siscovick D., and Newman A.B. Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. Am J Geriatr Cardiol 13 (2004) 81-90
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-266
20. Rosenbaum P.R., and Rubin D.B. The central role of propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
21. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
22. Joffe M.M., and Rosenbaum P.R. Invited commentary: propensity scores. Am J Epidemiol 150 (1999) 327-333
23. Rubin D.B. Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2 (2001) 169-188
24. Braitman L.E., and Rosenbaum P.R. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 137 (2002) 693-695
25. Normand S.T., Landrum M.B., Guadagnoli E., et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 54 (2001) 387-398
26. Brener S.J., Lytle B.W., Casserly I.P., Schneider J.P., Topol E.J., and Lauer M.S. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 109 (2004) 2290-2295
27. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27 (2006) 178-186
28. Love TE. Doing propensity analysis: the basics and matching. Available online at http://www.chrp.org/propensity/. Accessed: June 4, 2005.
29. Rosenbaum P.R. Observational studies (2002), Springer-Verlag, New York
30. Levesque R. Macro. In: Levesque R, ed. SPSS® programming and data management, ed 2. A guide for SPSS® and SAS® users. Available online at: http://www.spss.com/spss/data_management_book.htm. Accessed: June 4, 2005.
31. SPSS for Windows,Rel 13. [computer program] (2005), SPSS Inc, Chicago
32. Shlipak M.G., Smith G.L., Rathore S.S., Massie B.M., and Krumholz H.M. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 15 (2004) 2195-2203
33. Houghton A.R., and Cowley A.J. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?. Int J Cardiol 59 (1997) 7-10
34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
35. Rothwell P.M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005) 176-186
36. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
37. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?. J Am Geriatr Soc 50 (2002) 1297-1300
38. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 160 (2000) 685-693